Teva Pharmaceutical Industries - TEVA Stock Forecast, Price & News

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Teva Pharmaceutical Industries in the last year. There are currently 3 sell ratings, 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" TEVA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TEVA, but not buy additional shares or sell existing shares.
View TEVA analyst ratings or view top-rated stocks.

10 Wall Street analysts have issued twelve-month price objectives for Teva Pharmaceutical Industries' stock. Their TEVA share price forecasts range from $7.00 to $13.00. On average, they predict the company's stock price to reach $10.44 in the next year. This suggests a possible upside of 20.6% from the stock's current price.
View analysts price targets for TEVA or view top-rated stocks among Wall Street analysts.

Teva Pharmaceutical Industries' stock was trading at $8.01 at the beginning of the year. Since then, TEVA shares have increased by 8.1% and is now trading at $8.66.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 8th 2023.
View our TEVA earnings forecast.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced its earnings results on Thursday, November, 3rd. The company reported $0.56 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.58 by $0.02. The business earned $3.60 billion during the quarter, compared to the consensus estimate of $3.86 billion. Teva Pharmaceutical Industries had a negative net margin of 8.52% and a positive trailing twelve-month return on equity of 26.97%.

Teva Pharmaceutical Industries issued an update on its FY 2022 earnings guidance on Thursday, November, 10th. The company provided earnings per share guidance of $2.40-$2.60 for the period, compared to the consensus estimate of $2.50. The company issued revenue guidance of $14.80 billion-$15.40 billion, compared to the consensus revenue estimate of $15.46 billion.

158 employees have rated Teva Pharmaceutical Industries Chief Executive Officer Kåre Schultz on Glassdoor.com. Kåre Schultz has an approval rating of 90% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Teva Pharmaceutical Industries investors own include General Electric (GE), AT&T (T), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), Bank of America (BAC), Micron Technology (MU), Gilead Sciences (GILD), Johnson & Johnson (JNJ) and Cisco Systems (CSCO).

Teva Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA."

Teva Pharmaceutical Industries' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (3.75%), Abrams Capital Management L.P. (2.15%), Migdal Insurance & Financial Holdings Ltd. (1.93%), Phoenix Holdings Ltd. (1.88%), State Street Corp (1.34%) and Harel Insurance Investments & Financial Services Ltd. (1.27%). Insiders that own company stock include Brendan P O'grady, David Matthew Stark, Deborah A Griffin, Eli Shani, Eliyahu Sharon Kalif, Eric Drape, Hafrun Fridriksdottir, Mark Sabag, Pharmaceutical Co Ltd Takeda, Richard Daniell, Rosemary A Crane and Sven Dethlefs.
View institutional ownership trends.

Shares of TEVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TEVA stock can currently be purchased for approximately $8.66.

Teva Pharmaceutical Industries (NYSE:TEVA) has a market capitalization of $9.62 billion and generates $15.88 billion in revenue each year. The company earns $417 million in net income (profit) each year or ($1.16) on an earnings per share basis.

The company employs 37,537 workers across the globe.

Teva Pharmaceutical Industries' mailing address is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. The official website for the company is www.tevapharm.com. The company can be reached via phone at (723) 914-8213, via email at kevin.mannix@tevapharm.com, or via fax at 972-3923-4050.